Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples